SOL-GEL TECHNOLOGIES news, videos and press releases
For more news please use our advanced search feature.
SOL-GEL TECHNOLOGIES - More news...
SOL-GEL TECHNOLOGIES - More news...
- Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement
- Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
- Sol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South Africa
- Sol-Gel Technologies Announces Management Realignment
- Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
- Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
- Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
- Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
- Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
- Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
- Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
- Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
- Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments
- Sol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
- Sol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
- Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
- Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Sol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference
- Sol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference
- Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
- Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
- Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®
